Log In
Print
BCIQ
Print
Print this Print this
 

tigatuzumab (CS-1008)

  Manage Alerts
Collapse Summary General Information
Company Daiichi Sankyo Co. Ltd.
DescriptionHumanized mAb targeting human death receptor 5 (DR5)
Molecular Target Tumor necrosis factor (TNF) receptor superfamily member 10b (TNFRSF10B) (DR5) (TRAILR2) (CD262)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today